A Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3002815 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2017
At a glance
- Drugs LY 3002815 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly
- 08 Jun 2017 Status changed from not yet recruiting to recruiting.
- 18 May 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.
- 18 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017.